FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Wills Robert James					2. Issuer Name and Ticker or Trading Symbol  CymaBay Therapeutics, Inc. [ CBAY ]										tionship of R all applicabl Director	Reporting Person(s) to Issuer Ite) 10% Owner			/ner
(Last)	(First)	(1)	/liddle)		3. Date of Earliest Transaction (Month/Day/Year) 01/25/2023										Officer (gi below)	ve title		Other (s below)	pecify
C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
(Street) NEWARK	CA	9	4560												Form filed	l by More t	than C	ne Reportin	g Person
(City)	(State	) (2	ľip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				h/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Di			i. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	v			(A) or (D)	Price	Transaction (Instr. 3 and				(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Co		e (Instr. Se		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)		7. Title and Amour Securities Underly Derivative Securit 3 and 4)		erlying	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction	s Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	de	v	(A)	(D)	Date Exercisab		xpiration ate	Title		Amount or Number of Shares		(Instr. 4)	on(s)		
Stock Option (right to buy)	\$7.8	01/25/2023			A		25,000		(1)	0	1/24/2033		nmon ock	25,000	<b>\$0</b>	25,000	0	D	

## Explanation of Responses:

1. The option vests as to 1/12 of the underlying shares monthly from January 1, 2023.

/s/ Sujah Shah, as attorney-in-fact for Robert J. Wills 01/26/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.